AJP - Endo AJP: Heart and Circulatory Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 287: E1057-E1063, 2004. First published August 17, 2004; doi:10.1152/ajpendo.00313.2004
0193-1849/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/6/E1057    most recent
00313.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, M. C.
Right arrow Articles by Cherrington, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, M. C.
Right arrow Articles by Cherrington, A. D.

Portal infusion of a selective serotonin reuptake inhibitor enhances hepatic glucose disposal in conscious dogs

Mary Courtney Moore,1,2 Catherine A. DiCostanzo,1 Dominique Dardevet,1 Margaret Lautz,1 Ben Farmer,1 Doss W. Neal,1 and Alan D. Cherrington1,2

1Department of Molecular Physiology and Biophysics, and 2Diabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

Submitted 15 July 2004 ; accepted in final form 10 August 2004

Intraportal delivery of serotonin enhanced net hepatic glucose uptake (NHGU) during a hyperinsulinemic hyperglycemic clamp, but serotonin elevated catecholamines and can cause gastrointestinal distress. We hypothesized that the selective serotonin reuptake inhibitor (SSRI) fluvoxamine would enhance NHGU without side effects. Arteriovenous difference and tracer ([3-3H]glucose) techniques were used in conscious 42-h-fasted dogs. Experiments consisted of equilibration (–120 to –30 min), basal (–30 to 0 min), and experimental (EXP; 0–270 min) periods. During EXP, somatostatin, fourfold basal intraportal insulin, basal intraportal glucagon, and peripheral glucose (to double the hepatic glucose load) were infused. Saline (SAL) was infused intraportally during 0–90 min (P1), and fluvoxamine was infused intraportally at 0.5, 1, and 2 µg·kg–1·min–1 from 90 to 150 (P2), 150 to 210 (P3), and 210 to 270 (P4) min, respectively, in the FLUV group (n = 8). The SAL group (n = 9) received intraportal saline during 0–270 min. NHGU in SAL was 13.9 ± 1.7 and 17.0 ± 2.0 µmol·kg–1·min–1 in P3–P4, respectively, while NHGU in FLUV averaged 19.7 ± 2.8 and 26.6 ± 3.0 µmol·kg–1·min–1 (P < 0.05 vs. SAL). Net hepatic carbon retention was greater (P < 0.05) in FLUV than in SAL (17.6 ± 2.6 vs. 13.9 ± 2.7 and 23.8 ± 3.0 vs. 14.4 ± 3.3 µmol·kg–1·min–1 in P3–P4, respectively), and final hepatic glycogen concentrations were 50% greater in FLUV (P < 0.005). Nonhepatic glucose uptake was greater in SAL than in FLUV at 270 min (P < 0.05). Catecholamine concentrations remained basal, and the animals evidenced no distress. Thus fluvoxamine enhanced NHGU and hepatic carbon storage without raising circulating serotonin concentrations or causing stress, suggesting that hepatic-targeted SSRIs might be effective in reducing postprandial hyperglycemia in individuals with diabetes or impaired glucose tolerance.

glycemia; liver; portal vein; hepatic glucose uptake; nonhepatic glucose uptake



Address for reprint requests and other correspondence: M. C. Moore, Dept. of Molecular Physiology & Biophysics, 702 Light Hall, Vanderbilt Univ. School of Medicine, Nashville, TN 37232-0615 (E-mail: genie.moore{at}vanderbilt.edu)




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. M. Sanders, C. W. Wilkinson, G. J. Taborsky Jr., S. Al-Noori, W. Daumen, A. Zavosh, and D. P. Figlewicz
The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia
Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E853 - E860.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. C. Moore, K. Kimura, H. Shibata, T. Honjoh, M. Saito, C. A. Everett, M. S. Smith, and A. D. Cherrington
Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E225 - E231.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. C. Moore, C. A. DiCostanzo, D. Dardevet, M. Lautz, B. Farmer, and A. D. Cherrington
Interaction of a selective serotonin reuptake inhibitor with insulin in the control of hepatic glucose uptake in conscious dogs
Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E556 - E563.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.